The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp630
EOSINOPHILIC ESOPHAGITIS
Date
May 7, 2023
Explore related products in the following collection:
This 90 minute session is designed to link junior faculty/GI fellows/other trainees who are interested in pursuing a clinical/research career in diseases of the upper gastrointestinal tract with established clinician/researcher experts in the field. One of each pair of the 5 expert pairs will give a short talk to the audience on a range of upper GI tract disorders, focusing on an overview of the disease, the knowledge and tools needed to gain expertise, what the expert perceives as future opportunities for expertise and/or research in this disease and general advice on how to advance personally and nationally in this field. At the conclusion of the didactic session (50 minutes), a 40 minute session will follow, with each pair of subject experts stationed at 5 different stations, to engage with a group of interested junior faculty/trainees. This will give the opportunity for attendees to gather and ask more individualized questions and start a mentoring relationship with one of the faculty. At the conclusion, it is hoped that contact information will be exchanged between faculty and junior faculty member to continue the mentoring relationship.
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
The field of EoE is undergone remarkable and dramatic changes in the last decade. With the advent of biologics, a better understanding of all current treatment options and how to pick the right option for a given patient is needed…
A family history of gastric cancer (GC) is a risk factor for developing this malignancy and portends an increased risk of precursor lesions such as gastric intestinal metaplasia (GIM)…